Metabolomics, Proteomics, and Epigenetics
February
Why Oncologists Must Tailor Clinical Features to Their Needs
Promise and Pitfalls Along the Path to Personalized Care
The Duke Cancer Institute
To help oncology providers better understand drug mechanisms of action, and the economic implications of their use.
Review of the most recent evidence-based literature discussing breast, colorectal, lung, and ovarian cancers, in addition to melanoma and multiple myeloma.
How Much Do We Spend and How Can We Spend It Better?
Insights Into Value-Based Insurance Design in Oncology
Radical Changes in Payment Incentives and Elimination of Low-Value Care
Health Plans Continue to Seek Methods to Curtail Cancer Costs
Grim Reality Is a Bitter Pill to Swallow: Interview with Michael P. Link, MD, ASCO President
The Challenges Facing Oncologists Are Formidable
A New Era in Targeted Treatment Has Begun
Advertisement
Advertisement
Trending on AJMC
1
The Evolving Role of Subcutaneous Therapies in EGFR+ NSCLC
2
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
3
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
4
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
5
